C000245561 Performance — Amplify Treatments, Testing and Advancements ETF

Data updated: 2024-08-27

In the 12 months to Jun 2024 the fund lost a net $2.8M, and assets reached $9.24M.

C000245561 Growth of $100

What $100 invested in Amplify Treatments, Testing and Advancements ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.

PeriodC000245561Category average
Since data start (Jan 2024 – Jun 2024)$95$104

C000245561 Annual Returns

Calendar-year total returns of Amplify Treatments, Testing and Advancements ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.

YearTotal return
2024 (Jan–Jun)−5.36%

C000245561 Monthly Returns

Monthly total returns as reported on SEC Form N-PORT.

YearJanFebMarAprMayJunJulAugSepOctNovDec
2024−5.9%−0.5%+0.8%−6.6%+11.5%−3.6%——————

C000245561 Risk

Risk measures from monthly returns over Jan 2024 – Jun 2024.

  • Best month: +11.48% (May 2024)
  • Worst month: −6.63% (Apr 2024)

C000245561 Fund Flows

Monthly money in and out of Amplify Treatments, Testing and Advancements ETF, from SEC Form N-PORT.

  • 12-month net flow: −$2.8M
  • 12-month gross sales (incl. reinvestments): $906K
  • Sales ÷ redemptions: 0.25×
MonthSalesRedemptionsNet flow
Jun 2024$906K$1.9M−$1.0M
May 2024$0$0$0
Apr 2024$0$841K−$841K
Mar 2024$0$0$0
Feb 2024$0$908K−$908K
Jan 2024$0$0$0

C000245561 Assets Under Management

Net assets of Amplify Treatments, Testing and Advancements ETF by report date, from SEC N-PORT filings.

Report dateNet assets
2024-06-30$9.24M
2024-03-31$11.10M

For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.